IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v45y2022i5d10.1007_s40264-022-01176-1.html
   My bibliography  Save this article

Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review

Author

Listed:
  • Benjamin Kompa

    (Harvard Medical School
    CAUSALab, Harvard T.H. Chan School of Public Health)

  • Joe B. Hakim

    (Harvard-MIT)

  • Anil Palepu

    (Harvard-MIT)

  • Kathryn Grace Kompa

    (Tufts University School of Medicine)

  • Michael Smith

    (Harvard T.H. Chan School of Public Health)

  • Paul A. Bain

    (Countway Library of Medicine, Harvard Medical School)

  • Stephen Woloszynek

    (Beth Israel Deaconess Medical Center)

  • Jeffery L. Painter

    (GlaxoSmithKline)

  • Andrew Bate

    (GlaxoSmithKline
    University of London
    NYU Grossman School of Medicine)

  • Andrew L. Beam

    (Harvard Medical School
    CAUSALab, Harvard T.H. Chan School of Public Health
    Harvard T.H. Chan School of Public Health)

Abstract

Introduction Artificial intelligence based on machine learning has made large advancements in many fields of science and medicine but its impact on pharmacovigilance is yet unclear. Objective The present study conducted a scoping review of the use of artificial intelligence based on machine learning to understand how it is used for pharmacovigilance tasks, characterize differences with other fields, and identify opportunities to improve pharmacovigilance through the use of machine learning. Design The PubMed, Embase, Web of Science, and IEEE Xplore databases were searched to identify articles pertaining to the use of machine learning in pharmacovigilance published from the year 2000 to September 2021. After manual screening of 7744 abstracts, a total of 393 papers met the inclusion criteria for further analysis. Extraction of key data on study design, data sources, sample size, and machine learning methodology was performed. Studies with the characteristics of good machine learning practice were defined and manual review focused on identifying studies that fulfilled these criteria and results that showed promise. Results The majority of studies (53%) were focused on detecting safety signals using traditional statistical methods. Of the studies that used more recent machine learning methods, 61% used off-the-shelf techniques with minor modifications. Temporal analysis revealed that newer methods such as deep learning have shown increased use in recent years. We found only 42 studies (10%) that reflect current best practices and trends in machine learning. In the subset of 154 papers that focused on data intake and ingestion, 30 (19%) were found to incorporate the same best practices. Conclusion Advances from artificial intelligence have yet to fully penetrate pharmacovigilance, although recent studies show signs that this may be changing.

Suggested Citation

  • Benjamin Kompa & Joe B. Hakim & Anil Palepu & Kathryn Grace Kompa & Michael Smith & Paul A. Bain & Stephen Woloszynek & Jeffery L. Painter & Andrew Bate & Andrew L. Beam, 2022. "Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review," Drug Safety, Springer, vol. 45(5), pages 477-491, May.
  • Handle: RePEc:spr:drugsa:v:45:y:2022:i:5:d:10.1007_s40264-022-01176-1
    DOI: 10.1007/s40264-022-01176-1
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-022-01176-1
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-022-01176-1?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:45:y:2022:i:5:d:10.1007_s40264-022-01176-1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.